The strong YORVIPATH growth and positive operating income signal a fundamental inflection point. Monitor Q2 2026 for initial YUVIWEL revenue and the PRV sale proceeds, which will further strengthen liquidity. The convertible note conversion eliminates $575M in debt, potentially improving equity quality.
ASND drugs
ASND drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $246.14entry
- T+1 · 6mo ago −3.04%α −3.87% · $238.66
- T+5 · 6mo ago −1.04%α −2.54% · $243.58
- T+20 · 5mo ago −11.92%α −15.06% · $216.79
- T+60 · 3mo ago −1.09%α −4.93% · $243.45
Price Chart
How similar events traded
Executive Summary
Ascendis Pharma reported Q1 2026 revenue of €246.6M (+144% YoY), driven by YORVIPATH sales tripling to €196.9M. Operating profit turned positive to €24.8M vs a loss of €104.2M, and net profit of €629.3M included a €679.0M deferred tax asset recognition. Subsequent events include FDA approval of YUVIWEL and a $187.5M PRV sale, strengthening the balance sheet.
Key Facts
- Revenue €246.6M, up 144% YoY (Q1 2025: €100.95M)
- Operating profit €24.8M vs loss of €104.2M YoY
- Net profit €629.3M (includes €679.0M deferred tax asset recognition)
- Basic EPS €10.20 vs -€1.58 YoY
- YORVIPATH revenue €196.9M, up 341% YoY
- Cash and cash equivalents €572.8M at March 31, 2026
- YUVIWEL (navepegritide) FDA approval for achondroplasia in February 2026
- Agreement to sell Rare Pediatric Disease PRV for $187.5M on May 6, 2026
- Completed conversion of $575M convertible notes into equity on May 6, 2026
Financial Impact
Revenue increased by €145.6M YoY; operating profit improved by €129.0M; net profit includes €679.0M non-cash deferred tax benefit
Risk Factors
- BioMarin patent litigation (ITC trial ongoing) could impact YUVIWEL commercialization
- Foreign exchange headwinds (USD/EUR volatility) may affect reported revenue
- Uncertainty around tariff measures on pharmaceutical products
- Sustained profitability depends on continued commercial execution for YORVIPATH and YUVIWEL
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001612042-26-000005 |
| Document: 0001612042-26-000005-index-headers.html | 0001612042-26-000005 |
| Document: 0001612042-26-000005-index.html | 0001612042-26-000005 |
| Document: 0001612042-26-000005.txt | 0001612042-26-000005 |
Track record
41 reports on ASND
14 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.63 −0.12% settles Feb 12
- Nov 12, 20263d ago 6-K Neutral 2/10 Entry $267.07 Now $271.63 +1.71% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.63 +1.71% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.63 +1.71% settles Feb 10
- Nov 6, 20269d ago 6-K Bullish 6/10 Entry $259.85 Now $271.63 +4.53% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.63 +5.77% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.63 +7.17% settles Feb 3
- Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.63 +8.58% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.63 +10.49% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.63 +20.59% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers